Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes



Status:Completed
Conditions:Diabetic Neuropathy, Neurology, Diabetes
Therapuetic Areas:Endocrinology, Neurology
Healthy:No
Age Range:18 - 65
Updated:11/30/2013
Start Date:October 2012
End Date:August 2014
Contact:Lina Willis
Email:clinicaltrials@cebix.com
Phone:858-729-6501

Use our guide to learn which trials are right for you!

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects With Mild to Moderate Diabetic Peripheral Neuropathy


The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated
synthetic human C-peptide) following weekly subcutaneous administration for 12 months in
type 1 diabetes mellitus patients (T1DM) with mild to moderate diabetic peripheral
neuropathy (DPN).


Key Inclusion Criteria:

- Give informed consent;

- 18-65 years old;

- Have type 1 diabetes mellitus for a minimum of 5 years, with a stable diabetic
regimen (for at least 3 months);

- Have clinical signs of diabetic peripheral neuropathy at screening;

- Have abnormal sural nerve conduction observed bilaterally during screening;

- Be C-peptide deficient;

- Be in good general health (besides having type 1 diabetes mellitus);

- Practice effective contraception during and for at least 12 weeks after study
participation;

- Have a body mass index (BMI) ≥18.0 and <35.0 kg/m2.

Key Exclusion Criteria:

- Any significant cardiovascular, hematological, lymphatic, immunologic, urologic,
dermatologic, psychiatric, renal, hepatic, pulmonary, endocrine (except for diabetes
mellitus), central nervous, gastrointestinal, or other major disease;

- Unstable or inadequate glucose control;

- Any clinically significant laboratory value at screening;

- Occurrence of a severe, unexplainable hypoglycemic event (defined as requiring the
assistance of another individual) within 6 months of Day 0, or recurrent episodes of
non-severe hypoglycemia (≥3 per week on average) that are deemed clinically
significant by the Investigator;

- Have had an islet cell, kidney, and/or pancreas transplant;

- If female, is pregnant or lactating;

- History of alcohol or substance abuse within 2 years;

- Positive screen for hepatitis B, hepatitis C antibody, or human immunodeficiency
virus (HIV) antibody;

- Initiation of treatment or change of dose of medication that could affect peripheral
nerve function within 60 days;

- Previous treatment with CBX129801 or unmodified C-peptide;

- Receipt of an investigational product or therapeutic device, or participation in a
drug research study, within a period of 30 days;

- Chronic use of oral steroids or use of Ampyra (dalfampridine) within 60 days.
We found this trial at
10
sites
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Coeur D Alene, ID
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
?
mi
from
Helena, MT
Click here to add this to my saved trials
?
mi
from
Henderson, NV
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials